Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSeneca Growth Regulatory News (HYG)

Share Price Information for Seneca Growth (HYG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 13.50
Bid: 10.00
Ask: 17.00
Change: 0.00 (0.00%)
Spread: 7.00 (70.00%)
Open: 13.50
High: 13.50
Low: 13.50
Prev. Close: 13.50
HYG Live PriceLast checked at -
Seneca Growth Capital VCT is an Investment Trust

To provide shareholders with an attractive income and capital return by investing its funds in a portfolio of both unquoted and quoted UK MedTech companies which meet the relevant criteria under the VCT Rules.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

B Share Portfolio Update

21 Dec 2022 07:00

B Share Portfolio Update

B Share Portfolio Update

Seneca Growth Capital VCT Plc (the "Company")

21 December 2022

B Share Pool Investment Activity since 30 June 2022

Since the June 2022 interim results, the Company has completed seven additional investments, including one follow-on investment into Arecor Therapeutics Plc, three private company investments and three new AIM quoted investments, maintaining our goal of achieving a relatively even split between unquoted and quoted investments across a diverse spread of sectors. The investments made since 30 June 2022 are as follows:

Arecor Therapeutics Plc (“Arecor”) - £0.2m follow-on investment made in August 2022 following our initial £0.4m investment at IPO. Arecor is developing a portfolio of proprietary products in diabetes and other indications with its innovative proprietary formulation technology platform, Arestat™, and working with leading pharmaceutical and biotechnology companies to deliver enhanced reformulations of their therapies.Alderley Lighthouse Labs Ltd (“ALL”) - £0.5m invested in October 2022. ALL is a full service diagnostic facility in Alderley Park, with an initial focus on blood science and molecular diagnostics with capabilities to expand into histology and oncology. Oxford BioDynamics Plc (“OBD”) - £0.7m invested in October 2022. OBD is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.Bidstack Group Plc (“Bidstack”) - £1.1m invested in October 2022. Bidstack is an advertising technology company which provides dynamic, targeted and automated native in-game advertising for the global video games industry across multiple platforms.Northcoders Group plc (“Northcoders”) - £0.3m invested in November 2022. Northcoders is a market leading provider of coding and software development training for businesses and individuals. Geomiq Limited (“Geomiq”) - £0.3m invested in December 2022. Geomiq is a supply chain platform solution that allows engineers and procurement teams to shorten product development cycles and get products to market faster by leveraging technology and a machine-learning-powered matching system to connect buyers and sellers of custom manufactured parts. Convenient Collect Limited (“HubBox”) - £0.7m invested in December 2022. HubBox provides software for retailers to easily offer local pickup options at checkout for customers who want alternatives to home delivery. This software facilitates the offer of integrated flexible delivery options, including consolidation of multiple deliveries into single location/pick up points, helping to solve the ‘last mile problem’ for delivery providers, retailers and customers.

The B share pool remains well placed to make new investments and support existing B share portfolio companies with c.£5m in cash following the investment in HubBox and with a continuing fundraise under the current Offer.

B Share Pool Exits Update

The Company continues to harvest profits where possible for investors, and has made three full and partial exits to date in 2022, taking the total number of full and partial exits since 2019 to eight. The total weighted average return for exits achieved to date is 1.8x return. However, neither the exits achieved nor the valuations of the B share portfolio since 30 September 2022, the date of the last published unaudited Net Asset Value (“NAV”) per B share, have had a material impact on the NAV.

B Share Pool Dividends Update

The Company also continues to maintain its 3 pence per annum B share dividend, with its second interim dividend of 1.5 pence per B share for the year to 31 December 2022, which was paid on 16 December 2022. The Company has now paid a total of 12 pence per B share since the launch of the B share class in 2018.

The Company looks forward to providing a further update in Q1 2023.

This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation No 596/2014 which is part of English Law by virtue of the European (Withdrawal) Act 2018, as amended. Upon the publication of this announcement via a Regulatory Information Service, this information is now considered to be in the public domain.

For further information, please contact:

John Hustler, Seneca Growth Capital VCT Plc at john.hustler@btconnect.com

Richard Manley, Seneca Growth Capital VCT Plc at Richard.Manley@senecapartners.co.uk

Date   Source Headline
31st Mar 20205:30 pmGNWNet Asset Value(s)
26th Mar 20204:31 pmGNWAGM Venue Change
13th Mar 20204:14 pmGNWInterim Dividend
10th Mar 20202:28 pmGNWIssue of Equity
10th Mar 20207:00 amGNWB Share Net Asset Value
3rd Mar 20204:30 pmGNWIssue of Supplementary Prospectus
27th Feb 20207:00 amGNWFinal Results
9th Dec 20195:45 pmGNWDirectorate Change
27th Nov 20192:45 pmGNWIssue of Equity
20th Nov 20194:00 pmGNWDuplicate: Second Interim Dividend
28th Oct 20197:00 amGNWSecond interim dividend
10th Oct 20196:30 pmGNWDirector/PDMR Shareholding
8th Oct 20191:55 pmGNWIssue of Equity
8th Oct 20197:00 amGNWUpdate for the quarter ended 30 September 2019
17th Jul 20198:00 amGNWCorrection: Offer for Subscription
16th Jul 20195:27 pmGNWOffer for Subscription
10th Jul 20195:20 pmGNWHalf-year report
18th Jun 20199:16 amRNSHolding(s) in Company
10th Jun 20196:14 pmRNSResult of AGM
16th May 20197:00 amRNSSecond Interim Dividend
29th Apr 20198:52 amRNSFinal Results
25th Apr 20197:00 amRNSNet Asset Value(s)
5th Apr 201912:47 pmRNSIssue of Equity
3rd Apr 201912:46 pmRNSIssue of Equity
29th Mar 20195:20 pmRNSRevised timetable
13th Mar 201912:03 pmRNSExtension of Offer
7th Mar 20193:22 pmRNSIssue of Equity
6th Mar 201910:30 amRNSInterim Dividend
6th Mar 20198:39 amRNSNet Asset Value(s)
28th Dec 20187:00 amRNSDividend Declaration
19th Dec 20182:21 pmRNSIssue of Equity
18th Dec 20189:56 amRNSUpdate on Hallmarq
17th Dec 20184:43 pmRNSReduction of Capital
29th Nov 20181:53 pmRNSHolding(s) in Company
23rd Nov 20187:00 amRNSUpdate for the quarter ended 30 September 2018
27th Sep 201810:59 amRNSIssue of Equity
23rd Apr 201812:43 pmRNSHolding(s) in Company
22nd May 201712:59 pmRNSHolding(s) in Company
24th Feb 201610:42 amRNSScancell to present at Biotech Capital
16th Feb 20159:47 amRNSHoldings in Company
24th Oct 20133:53 pmRNSInterim Management Statement
22nd Mar 20127:00 amRNSFinal Results
29th Oct 201011:18 amRNSInterim Management Statement
7th Sep 201011:34 amRNSDirector's Dealings
5th Aug 20107:00 amRNSHalf Yearly Report
7th May 20107:00 amRNSResults of AGM and IMS to 31 March 2010
31st Mar 20104:48 pmRNSAnnual Financial Report
22nd Jan 201012:26 pmRNSDeclaration of Interim Dividend
24th Sep 20099:43 amRNSDirector's Dealing
22nd Sep 200910:10 amRNSPortfolio Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.